Developing targeted antibiotics to fight resistant Pseudomonas aeruginosa infections
Official title: Targeted development and selective delivery of small molecule antibiotics for the treatment of multidrug resistant Pseudomonas aeruginosa infections
Funded at University of North Carolina Asheville · NIH-10279394 · Data updated 2026-11-12
This study is working on developing new antibiotics to help people who have tough infections caused by a bacteria called Pseudomonas aeruginosa, which doesn't respond well to current treatments.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Asheville NIH-funded |
| Lab location | 1 site (Asheville, United States) |
| Project start | July 1, 2021 |
| Project end | June 30, 2025 |
| Funding year | 2021 |
| Award (this year) | $384,353 |
| NIH project number | 1R15AI163474-01 |
| Project ID | NIH-10279394 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by multidrug resistant Pseudomonas aeruginosa.
✕Less likely to help
Patients with infections caused by bacteria that are not multidrug resistant or those with non-bacterial infections may not benefit from this research.
What this research studies
This research focuses on creating new small molecule antibiotics specifically designed to combat multidrug resistant Pseudomonas aeruginosa infections, which are a significant threat due to their resistance to existing treatments. The approach involves modifying an existing drug to target a crucial protein in the bacteria, enhancing the effectiveness of the antibiotic. By understanding how this protein functions and how the antibiotic can be delivered more effectively, the research aims to provide a novel treatment option for patients suffering from these infections.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antibiotics that can treat infections caused by multidrug resistant bacteria, potentially saving lives.
How similar studies have gone: While the approach of targeting ATP synthase is relatively novel, previous research has shown promise in developing antibiotics that target unique bacterial mechanisms.
Where this research is happening
-
University of North Carolina Asheville
Asheville, United States Active
Researchers
- Principal investigator: Wolfe, Amanda Lynn — University of North Carolina Asheville
- Study coordinator: Wolfe, Amanda Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.